製品名:(S)-1-Phenylethylamine

IUPAC Name:(1S)-1-phenylethan-1-amine

CAS番号:2627-86-3
分子式:C8H11N
純度:98%
カタログ番号:CM117469
分子量:121.18

包装単位 有効在庫 価格(USD) 数量
CM117469-100g in stock ưư

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:2627-86-3
分子式:C8H11N
融点:-
SMILESコード:N[C@H](C1=CC=CC=C1)C
密度:
カタログ番号:CM117469
分子量:121.18
沸点:
MDL番号:MFCD00064406
保管方法:Keep in a tight container and store at ambient temperature,protect from light

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Mavacamten
CAMZYOS(Mavacamten) was recently approved in the European Union, following its approval in the U.S. and other markets worldwide, and is the first and only cardiac myosin inhibitor approved to treat adult patients with symptomatic obstructive hypertrophic cardiomyopathy(HCM).
Mavacamten is a first-in-class, targeted inhibitor of cardiac myosin, reduces the number of myosin-actin cross-bridges and thus decreases excessive contractility characteristic of HCM.